ImmunoPrecise Antibodies Ltd. ( IPA) Stock. Should you Buy or Sell? $ 5.65
0.61 (9.74 %)
ImmunoPrecise Antibodies Ltd. Analysis
Updated on 10-09-2022| Symbol | IPA |
| Price | $5.65 |
| Beta | 0.126 |
| Volume Avg. | $15.09 thousand |
| Market Cap | $148.08 M |
| 52 Week Range | $3.51 - $7.16 |
ImmunoPrecise Antibodies Ltd. opened the day at $5.65 which is +'9.74 % on yesterday's close. ImmunoPrecise Antibodies Ltd. has a 52 week high of $7.16 and 52 week low of $3.51, which is a difference of $3.65. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $148.08 M and total net profit is $19364000 which means the company is trading at 7.65 times profit to market capitalization. Theoretically, if you were to buy ImmunoPrecise Antibodies Ltd. for $148.08 M, it would take 15 years to get your money back. ImmunoPrecise Antibodies Ltd. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
ImmunoPrecise Antibodies Ltd. Stock Forecast - Is ImmunoPrecise Antibodies Ltd. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Neutral | |
| ROA Score | Neutral | |
| DE Score | Neutral | |
| PE Score | Strong Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Buy |
Growth and Value
| PE Ratio | -8.278 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | -0.863 |
Valuing ImmunoPrecise Antibodies Ltd.
| Price Book Value Ratio | 1.837 | Price To Book Ratio | 1.837 |
| Price To Sales Ratio | 7.143 | Price Earnings Ratio | -8.278 |
How liquid is ImmunoPrecise Antibodies Ltd.
| Current Ratio | 4.045 |
| Quick Ratio | 3.603 |
Debt
| Debt Ratio | 0.195 | Debt Equity Ratio | 0.242 |
| Long Term Debt To Capitalization | 0.005 | Total Debt To Capitalization | 0.033 |
Latest news about ImmunoPrecise Antibodies Ltd.
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year 2023, on Wednesday, September 14, 2022, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise manag
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its financial results and recent business highlights for fourth quarter and full fiscal year 2022, on Friday, July 29, 2022, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise man
ImmunoPrecise Antibodies Ltd. (IPA) CEO Jennifer Bath on Q3 2022 Results - Earnings Call Transcript
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced today announced that it will host a conference call to discuss its financial results and recent business highlights for third quarter fiscal year 2022, on Wednesday, March 16th, 2022, at 10:30 a.m. ET. The financial results will be issued in a press release prior to the call.
Immunoprecise Antibodies Ltd IPA has released preclinical data for the PolyTope TATX-03 COVID-19 antibody cocktail. [ALERT] Nic Chahine shares his Bear Market Beating options trading strategy.
About ImmunoPrecise Antibodies Ltd.
Description :
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
